I_Invest, I was just wondering. In a previous statement, Moro stated that similar initiatives to BioCurex China were ongoing in other countries. If Moro did get a lab to license the test in another country, I don't think that would be considered a similar initiative. That would be just a licensee. Unfortunately, I do not think that to be the case. From Moro's statements below, you are probably looking at a BioCurex India or something similar. If I am correct, look for that venture to also be ill thought out and poorly planned.
Moro June: "7) Given our current cash position, our BioCurex China initiative is delayed for the time being. BioCurex China will be set in high gear immediately after we secure financing."
Moro March: "Also, I would not restrict it to China because we are simultaneously working on similar initiatives in other countries."
Moro Feb: "we are setting up shop in China, which will be followed by other similar enterprises in other countries,"
Moro Feb: "3) We shall not sell product to other clinical labs but rather perform the tests and report the results. This reduces the regulatory burden and doubles or trebles the revenue per test."
If the last statement above was true, why would you need much money for that approach. Something does not make sense to now have testing in China on hold for funding unless what Moro stated above was not possible.
AI
